ArticleCancer discovery2020

Correction: Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.

PubMed ↗Publisher ↗

No numbers read from the abstract.